RELMADA THERAPEUT.DL-001
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more
RELMADA THERAPEUT.DL-001 (4E2) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, RELMADA THERAPEUT.DL-001 (4E2) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
RELMADA THERAPEUT.DL-001 - Net Assets Trend (None–None)
This chart illustrates how RELMADA THERAPEUT.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RELMADA THERAPEUT.DL-001 (None–None)
The table below shows the annual net assets of RELMADA THERAPEUT.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to RELMADA THERAPEUT.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
RELMADA THERAPEUT.DL-001 Competitors by Market Cap
The table below lists competitors of RELMADA THERAPEUT.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lanzhou Greatwall Electrical Co Ltd
SHG:600192
|
$352.74 Million |
|
Tejon Ranch Co
NYSE:TRC
|
$352.90 Million |
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
$352.91 Million |
|
WAORF
PINK:WAORF
|
$352.92 Million |
|
Shenzhen Genvict Technologies Co Ltd
SHE:002869
|
$352.50 Million |
|
Chuzhou Duoli Automotive Technology Co. Ltd. A
SHE:001311
|
$352.50 Million |
|
CHORUS AVIAT.(VOT.+VAR.)
F:1H0
|
$352.49 Million |
|
Better Collective A/S
PINK:BTRCF
|
$352.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RELMADA THERAPEUT.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares RELMADA THERAPEUT.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently RELMADA THERAPEUT.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares RELMADA THERAPEUT.DL-001's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RELMADA THERAPEUT.DL-001 (4E2) | €- | N/A | N/A | $352.71 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |